What is BrainWaveBank?
BrainWaveBank operates at the intersection of medical-grade technology and neuroscience, providing a sophisticated at-home platform designed to monitor functional brain health. The company's core value proposition lies in its ability to facilitate early diagnosis and continuous patient monitoring, which are essential for the efficacy of modern clinical trials. By integrating cutting-edge analytics, BrainWaveBank enables researchers and healthcare providers to obtain high-fidelity data, thereby streamlining the delivery of novel therapies for complex brain disorders. The firm's market position is defined by its focus on scalable, remote-monitoring solutions that bridge the gap between traditional clinical settings and patient-centric care models.
How much funding has BrainWaveBank raised?
BrainWaveBank has raised a total of $3.6M across 3 funding rounds:
Unspecified
$1.2M
Unspecified
$1.4M
Other Financing Round
$967K
Unspecified (2017): $1.2M with participation from Clarendon Fund Managers, techstart NI, Invest Northern Ireland, and Angel CoFund
Unspecified (2020): $1.4M led by Angel CoFund, Clarendon Fund Managers, British Business Investments, Techstart Ventures, and Par Equity
Other Financing Round (2020): $967K supported by Par Equity
Key Investors in BrainWaveBank
Angel CoFund
A £100M investment fund that collaborates with sector-focused angel investors to support promising UK businesses through co-investment and capital growth strategies.
British Business Investments
A government-owned economic bank dedicated to assisting UK enterprises by providing diverse financial support options and fostering innovation through strategic investment schemes.
Par Equity
An investment banking firm specializing in providing capital and strategic guidance to high-growth companies, with a focus on driving operational excellence.
What's next for BrainWaveBank?
With the recent infusion of capital, BrainWaveBank is poised to scale its operational infrastructure and expand its clinical trial support capabilities. The strategic roadmap likely involves deepening its data analytics engine to enhance the predictive accuracy of its diagnostic platform. As the company transitions into a more mature phase of enterprise-level growth, the focus will shift toward securing broader regulatory approvals and establishing strategic partnerships with global pharmaceutical entities. This expansion is critical for maintaining a competitive edge in the rapidly evolving landscape of neuro-health, where the demand for efficient, technology-enabled patient monitoring continues to rise.
See full BrainWaveBank company page
